Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Peloquin

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study GroupR Hafner, J A Cohn, D J Wright, et al.
Antimicrobial Agents and Chemotherapy|November 17, 2020
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy RegimensG L Drusano, Sarah Kim, Mohammed Almoslem, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2023
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitusY Alkabab, J Warkentin, J Cummins, et al.
Tuberculosis (Edinburgh, Scotland)|November 19, 2003
Direct lung delivery of para-aminosalicylic acid by aerosol particlesN Tsapis, D Bennett, K O'Driscoll, et al.
Arthritis and Rheumatism|November 9, 2012
Vitamin D, race, and experimental pain sensitivity in older adults with knee osteoarthritisT L Glover, B R Goodin, A L Horgas, et al.
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Antimicrobial Agents and Chemotherapy|June 1, 2017
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for TuberculosisC A Peloquin, G E Velásquez, L Lecca, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 8, 2004
Pharmacokinetics of ethambutol in children and adults with tuberculosisM Zhu, W J Burman, J R Starke, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 17, 2006
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosisJ L Johnson, D J Hadad, W H Boom, et al.
IJTLD Open|April 24, 2024
Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TBP S Rao, K Reed, N Modi, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study GroupR Hafner, J A Cohn, D J Wright, et al.
Antimicrobial Agents and Chemotherapy|November 17, 2020
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy RegimensG L Drusano, Sarah Kim, Mohammed Almoslem, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2023
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitusY Alkabab, J Warkentin, J Cummins, et al.
Tuberculosis (Edinburgh, Scotland)|November 19, 2003
Direct lung delivery of para-aminosalicylic acid by aerosol particlesN Tsapis, D Bennett, K O'Driscoll, et al.
Arthritis and Rheumatism|November 9, 2012
Vitamin D, race, and experimental pain sensitivity in older adults with knee osteoarthritisT L Glover, B R Goodin, A L Horgas, et al.
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Antimicrobial Agents and Chemotherapy|June 1, 2017
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for TuberculosisC A Peloquin, G E Velásquez, L Lecca, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 8, 2004
Pharmacokinetics of ethambutol in children and adults with tuberculosisM Zhu, W J Burman, J R Starke, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 17, 2006
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosisJ L Johnson, D J Hadad, W H Boom, et al.
IJTLD Open|April 24, 2024
Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TBP S Rao, K Reed, N Modi, et al.
Pageof 8